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1. Abstract 
 
The workshop "Applied Genomics in the Clinic" was organised in Istanbul on 17-19 
October 2012 within the context of JRC Enlargement and Integration Activities 
(E&IA). The main aim of the workshop was to get an overview of the state of the art 
of applied genomics in the clinical context in accession and candidate countries, as 
well as new members, to share best practices in EU and to evaluate these in the light 
of a public health perspective. There is a clear divide behind the genomic services 
offered in a country and the awareness among research scientists of the available 
genomic applications and the future impact of genomic technologies on health 
services and clinical approaches. In all countries there are a number of common 
obstacles that delay penetration of genomic technologies in clinical applications: lack 
of recognised experts (medical genetics has to be recognised as a medical specialty) 
lack of a regulatory framework that involves political determination of decision 
makers, lack of common databases on methods and experts, lack of on-going 
education for physicians and most importantly reimbursement of testing. Stronger 
connections and collaborations with the EU for research and technology transfer will 
function as leverage for these countries in adopting genomic tools and harmonising 
the quality of healthcare services they offer. It is very important to establish 
recognized objective state of the art guidelines for application of genomic 
technologies in clinical practice. Such guidelines adopted by countries could 
contribute to form the basis of reimbursement policies at national and cross border 
levels. In addition establishing reliable, not for profit, open access databases for 
building reference datasets for correct and efficient interpretation of complex data 
generated by advanced genomic technologies will speed up adoption of the 
technology in the clinic. 
 
2. Executive Summary 
 
In the coming decade, advanced genomic technologies are expected to have a 
substantial impact on, and even change current frames of public health. Disease 
classification and taxonomy, molecular diagnostics, drug development processes, 
stratified and personalized medicine as well as lifestyle and nutrition choices are 
some of the areas that will be directly affected. While the cost of whole genome 
sequencing reduces and test specificity and sensitivities improve, huge amounts of 
data are being generated that require proper management, guided and monitored 
validation, extensive analyses and customised clinical interpretation to help serve 
the medical community and health of individual patients in general. 
Technology has evolved at such a rapid pace that today a consumer can have his or 
her entire genome sequenced by a single company in a matter of days for less than 
$ 5,000, though the addition of interpretation may extend this timeframe. With the 
next-generation sequencing technologies currently being developed, the cost is 
projected to continue to decline significantly over the next few years, to the point 
that large-scale genome sequencing is expected to become comparable in cost to a 
single gene test or to a diagnostic imaging test such as a computed tomography (CT) 
scan (Mardis, 2006). Given the rapid technological advances, the potential effect on 
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the lives of patients and the increasing use of genomic information in clinical care, it 
is important to address how genomics data can be integrated into the clinical 
setting. Genetic tests are already used to assess the risk of breast and ovarian 
cancers, to diagnose recessive diseases such as cystic fibrosis, to determine drug 
dosages based on individual patient metabolism, and to identify therapeutic options 
for treating lung and breast tumours, melanoma, and leukaemia. 
Recent studies have also demonstrated the usefulness of genomics for diagnosing 
disease and guiding treatment in the clinic. For example, genetic testing of the 
relatives of patients newly diagnosed with colon cancer has suggested a prevention 
strategy for identifying individuals with Lynch syndrome (Coates et al., 2011). 
Genomics data have been used to provide definitive diagnoses for patients with 
neuropathy, inflammatory bowel disease, and Proteus syndrome as well as to guide 
therapeutic care for patients with arterial calcifications, movement disorders, and 
Miller syndrome (Bainbridge et al., 2011; Lindhurst et al., 2011; Lupski et al., 2010; 
Ng et al, 2010; St. Hilaire et al., 2011; Worthey et al., 2011). Although applications 
of genomics technologies are currently limited in number, their number will only 
continue to increase. Thus, it is important to determine how genomic data can best 
be integrated with clinical practice so as to maximize patient benefit.  
It is becoming increasingly clear that large-scale genomic information would be 
integrated more fully into clinical practice, which meant that issues related to 
implementing this change needed to be addressed. On the other hand, most 
patients and health care providers have not yet realized just how broad an effect 
genomic discovery is likely to have on treatment course and health. 
 
The main aim of the workshop was to get an overview of the state of the art of 
applied genomics in the clinical context in accession and candidate countries, as 
well as new members, to share best practices in EU and to evaluate these in the 
light of a public health perspective. Experts from target countries attending the 
meeting as country representatives presented a summary of the molecular genetic/ 
genomic services available in their respective countries both from the clinical and 
research environment perspective. Selected speakers presented examples of 
current applications of diverse genomic technologies in healthcare services. The 
European Best Practice Guidelines for Genome-based Information and Technologies 
and the EU policy on rare diseases, including a summary on the legal basis for the 
developments of the EU Policy on rare diseases were also shared with the 
attendants. The European Project for Rare Diseases National Plans Development 
(EUROPLAN) is a project co-funded by the EU Commission (DG-SANCO) to promote 
and implement National Plans or Strategies to tackle rare diseases, to share 
relevant experiences within Countries, linking national efforts with a common 
strategy at European level. Participants also presented the situation in their 
respective countries regarding the elaboration and the implementation of Rare 
Diseases National Plans/Strategies. 
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3. Presentations and session highlights 
 
The morning session of the first day started with the welcome address given by Dr 
Laura Gribaldo from the European Commission's Joint Research Centre. She 
introduced the role of the Institute for Health and Consumer Protection (IHCP) at 
the JRC, as provider of scientific and technical support to the EU policies for the 
protection of European citizens in the areas of food, consumer products, chemicals 
and public health. Furthermore Dr. Gribaldo summarized the role of DG 
Enlargement in managing the process whereby countries join the European Union. 
The concepts of sharing knowledge, improve communication and strengthen 
networking have been identified as the basis of any harmonised effort to enlarge 
Europe. 
 
A general introduction on the University of Istanbul was given by Prof Ugur Ozbek, 
the local host. This University counts 20 faculties and 74 000 students, it has on 
going protocols with 56 Universities worldwide and 483 Erasmus Agreements. In 
terms of health services it counts 2 University Hospitals, a Cardiology Institute, an 
Oncology Institute and a Faculty of Dentistry, with a total of 3500 bed capacity, 2.5 
million outpatient/year and 100.000 in patient/year. The Institute of Experimental 
Medicine (DETAE) which co-hosted the meeting is dedicated solely to medical 
research, and it is one of the first and largest biomedical research institutes in 
Turkey established in 1992. Five departments belong to the Institute: Genetics, 
Immunology, Molecular Medicine, Neurosciences, and Animal Model Organisms. In 
the Genetics Department there are five units/laboratories: Tuberculosis Molecular 
Epidemiology unit, Diabetes research and application unit, Molecular Andrology 
unit, Whole genome sequencing laboratory (FLX-454-Ion torrent), Whole genome 
expression microarray laboratory (Illumina). They are partners in a number of 
European initiatives including Orphanet, ELN, MedGeNet (Euro-Mediterranean 
Network for Genetic Services), ITFOM and the FP7 project Epicure.  
 
In summary, they combine multidisciplinary research and education, coordination 
of the postgraduate programs on Immunology, Genetics, Molecular Medicine, 
Neuroscience and conduct competitive international projects in medical sciences 
through development of novel approaches for the prevention and diagnosis of 
common human diseases. Their strengths are: enthusiastic young scientists eager to 
learn new techniques, and expand their vision, established strong infrastructure for 
varying projects (a unique whole genome analysis laboratory in operation in 
Turkey), a suitable environment for collaborations on a complex disease like 
diabetes (diabetes centres, immunology and genetics departments all in one place).  
 
The first scientific session focused on new technologies like Single Nucleotide 
Polymorphism (SNP) Microarrays for Genotyping and Next Generation Sequencing 
(NGS).  
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Dr Jeremy Sujie Cao from BGI, one of the largest genomic organizations in the 
world, gave a presentation on "Application of Next Generation Sequencing in 
Human Disease Research and Clinical Application", showing how the BGI Healthcare 
Platform provides a series of hereditary disease testing services. Monogenic disease 
and hearing impairment tests are available at all life stage. At the prenatal stage, 
Non-Invasive Fetal Trysomy (NIFTY) test is significantly better than other 
conventional prenatal screening methods available at the present time. For a new 
born, inherited metabolic disease screening can be applied. Non-invasive and 
invasive test of chromosomal microdeletion/microduplication and Pre-implantation 
Genetic Diagnosis (PGD) technologies are still in research, but are coming soon and 
they are expected to be better strategies than the existing tests.  
 
Dr. Teodor Zamfirov, representative of Illumina Inc. from Bulgaria introduced us to 
which technological applications find way nowadays in the health care system, how 
the technology revolutionizes our deep understanding of the pathology process for 
many diseases, what is the prevention capacity employing genomic technology in 
the field of public health and medical conditions such as: Metabolic disorders, rare 
disease diagnostics, oncology, cardiology, personalized medicine, reproductive 
genetics, inherited diseases, pre and postnatal diagnosis and more. He exemplified 
various applications of the Illumina Inc. SNP microarrays in healthcare. Further in his 
presentation he described the latest developments regarding Illumina's personal 
next generation sequencer - The MiSeq.  This presentation was in depth and 
covered capacity, pricing, and the perspectives for further development of an entire 
new medical discipline - Personalized Medicine, based on the information coming 
out of the individual genome of each patient. 
 
In the second session of the first day, Prof. Angela Brand, Director of the European 
Centre for Public Health Genomics at the Institute for Public Health Genomics in 
Maastricht University, gave a presentation on European Best Practice Guidelines for 
Genome-based Information and Technologies – The Public Health Genomics 
European Network (PHGEN ) Declaration of Rome, a document endorsed by experts 
from the field of public health genomics representing key European and national 
organizations from policy making, academia and private sector.  The on-going 
success of genome wide association studies (GWAS) followed by chromosomal 
microarrays and eventually Whole Genome Shotgun (WGS ) in uncovering genetic 
risk factors for many common diseases has fuelled expectations of a new era of 
health care based on personalized treatment, early detection, and disease 
prevention. An optimal process is needed for appropriate translation of these new 
genomic discoveries into practice. The process should include mechanisms for 
developing an understanding of the relationship between these newly discovered 
factors and clinical outcomes (clinical validity), and the costs, benefits, and harms of 
genome-based technologies in real world settings (clinical utility). Furthermore, the 
process should facilitate the development of evidence-based guidelines for the use 
of genomic applications; and appropriate implementation of these applications in 
practice, including protection of individuals and communities against discrimination 
based on genetic information. The application of genome-based technologies and 
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informatics with the aim of combating diseases of public health significance brings a 
slew of ethical and social issues that challenge the normative frameworks used in 
clinical genetics until now.  
 
In the same session Dr Gribaldo summarised the EU policy on rare diseases, from 
the legal basis for the development of the EU Policy on rare diseases, to the 
emergence of concepts and initiatives surrounding rare diseases in Europe, the 
content of the Commission Communication and the Council Recommendation, and 
the history of support of rare diseases research at the European level, as well as the 
future way forward.  
 
In the afternoon session the country representatives discussed the state of the art 
of genomics penetration in clinical services in their respective countries. Country 
information ranging from the distribution of Genetic Diagnosis Centres, to the tests 
performed in different areas in a given country, availability of genetic testing in 
public and private (if any) laboratories has been presented. The state of medical 
genetics as a medical specialty, availability of genetic counselling and education for 
genetic counsellors, current coverage of rare diseases were among covered topics. 
The most frequently mentioned and underscored clinical applications within 
context were: dysmorphology testing, foetal examination, genetic counselling, 
management of congenital disorders, translation of research on complex disorders 
in Clinical genetics, chromosome analysis on peripheral blood samples, amniotic 
fluid, Chorionic Villus Sampling (CVS) or cord blood, Fluorescence In Situ 
Hybridization (FISH) in cytogenetic, and Capillary electrophoresis-based DNA 
sequencing Short Tandem Repeat (STR) analysis, Real-Time Polimerase Chain 
Reaction (RT-PCR), Quantitative Fluorescence Polimerase Chain Reaction (QF-PCR), 
Multiplex Ligation-dependent Probe Amplification (MLPA) and Array Comparative 
Genomic Hybridization (CGH )in molecular genetics. SNP based or chromosomal 
microarrays and NGS currently are not offered in any of the target countries of the 
workshop although there is awareness among researcher clinicians. 
 
Dr Ewa Stęphień, from the Department of Clinical Biochemistry, Jagiellonian 
University in Krakow, gave an overview on the reorganisation of Health System in 
Poland with procedures in medical genetics for physicians and laboratory 
diagnosticians, with special emphasis on educational and financial issues. She 
underscored new initiatives like the new Centre for rare cardiovascular diseases in 
Krakow) and international co-operation for genetic diagnostics of rare diseases that 
has been created with the incorporation (2011) of The Children’s Memorial Health 
Institute in Warsaw to the JOINT ACTION "Development of the European portal of 
rare disease and orphan drugs – ORPHANET Europe". Main achievements and main 
failures in clinical genetic diagnostics in Poland have been presented over a 
timeline. Organization of genetic counselling in Poland covered by National Health 
Fund is one of the achievements, like the education program in Medical Genetics 
(Specializations) for physicians and laboratory geneticists. New private laboratories 
and companies dedicated to clinical genetics have been established, and there is 
increasing number of diagnostic centres equipped with high throughput methods in 
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genetics. The main obstacles to the penetration of new technologies were 
presented as lack of comprehensive financial and education programs supporting 
development of scientific research in clinical genetics, dispersion of procedures over 
the list of guaranteed services (so-called "basket"), lack of interest in introduction of 
quality control system in genetic laboratories and limited availability to prenatal and 
pre-implantation genetic diagnostics (high costs).  
 
Dr Ahmet Yesilyurt from the University of Ankara, made an overview of current 
applications of medical genetics in Turkey. The Social Security Institute (SGK) is 
responsible for reimbursement; the frequency of the genetic test of each genetic 
centre can be followed with a global system called “MEDULLA” and PGD can be 
charged for just some disorders which can be treated via Human Leukocyte Antigen 
(HLA) typing compatible bone marrow transplantation from siblings. The most 
challenging problem presented was introducing a new test using next-generation 
sequencing since new technology hardly gains coverage by the social security 
system. Bottlenecks in genetic applications in Turkey were stated as: lack or 
insufficiency of infrastructures for genetic testing laboratories in some 
university/state hospitals, lack of well-educated staff to perform complex genetic 
tests, not homogeneous education programme (4 year) of medical geneticist, and 
insufficiency of bioinformaticians to evaluate complex and huge data from high 
throughput systems. 
 
Dr. Lejla Kapur-Pojskić presented data on Bosnia. Apparently at the moment any 
regulation is still lacking in Bosnia, as well as any official role for medical genetics. 
Laboratories are basically equipped with PCR facilities and RT PCR analysis are 
conducted on 30-40 patients per year, to detect leukaemia/lymphoma markers, as 
well as for Huntington diseases. Medical genetics is not recognised as specialty. 
Prenatal diagnosis is covered by insurances. There seems to be a lot of cross border 
patients'sample traffic to neighbouring Croatia where a special bilateral agreement 
for reimbursement of tests exists. 
 
Dr. Irena Drmic Hofman represented Croatia, as Chief of the Department of 
Pathology and Department of Biochemistry at the University Hospital Split and 
University of Split School of Medicine. Cytogenetics in Croatia is conducted in three 
hospitals: namely in the University Hospital “Rebro” Zagreb, Pediatric Clinic, Clinical 
Hospital Center “Sisters of Mercy,”and Clinical Hospital “Holly Spirit”, Clinic of 
Obstetrics & Gynecology. The services offered are mainly cytogenetic analysis of 
foetal and peripheral blood lymphocytes, amniotic fluid and spontaneous abortions, 
FISH analysis of bone marrow, FISH analysis for enumeration, microdeletion and 
microduplication syndromes, and whole chromosome painting, subtelomere 
analysis. In the Clinical Hospital Centre Sisters of Mercy Zagreb, molecular analysis 
of non-syndromic deafness, acondroplasia and hypocondroplasia, Rett syndrome 
and MLPA are carried out. The diagnostics focuses on monogenic diseases, 
leukaemia and lymphoma, tumour tissues, infectious diseases, risk factors, HLA 
typing and transfusion testing as well as molecular testing in Forensic Medicine.  
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Dr. Simona Dimitriu from the University of Medicine and Pharmacy "Victor Babes" 
in Timisoara, especially pointed out the consented effort in Romania for establishing 
a national plan for rare diseases which, she thinks, could serve as basis for a 
regulated, quality assured, up-to-date genetic testing environment in general. In 
Romania there seems to be a divide in the technology level among regions, and 
research and university settings. Chromosomal Microarray Analysis (CMAs) and NGS 
are finding way into the clinic through private laboratories. 
 
The day was ended with an informal round table discussion on the state of research 
in the represented countries and notes were taken that served as basis for the 
SWOT analysis of the last day. 
 
The first session of the second day was dedicated to the state-of-the-art 
applications of genomic technologies for clinical purposes. Dr. Francesca Grati from 
TOMA, Italy, gave a presentation on "Chromosomal microarrays in prenatal 
diagnosis: overview of the actual application and experiences”. With the 
development of advanced genome-wide or targeted techniques for interrogating 
the human genome, new methodologies are becoming available for prenatal 
screening and diagnosis, and the implementation of these methodologies into 
healthcare provisions will soon be changing the landscape of prenatal diagnosis. It is 
widely accepted that this technology can be considered as unique if not mandatory 
in challenging prenatal cases to clarify the pathogenicity of cytogenetic 
abnormalities and their prognosis. 
 
These challenging prenatal cases are: cases requiring a paternal uniparental disomy 
(UPD) condition exclusion on AF upon a mosaic trisomy for an imprinted 
chromosome is found in Chorionic Villi, cases having a high risk of false negative 
result due to the incompleteness of the combined cytogenetic analysis on CVS, 
cases with an apparently balanced ‘de novo’ rearrangement and in foetuses with US 
abnormalities and an apparently normal karyotype. 
 
On the other hand, it is still necessary to improve knowledge on human genome 
architecture in `normal` considered populations, on the entire phenotypic spectrum 
of microdeletion and microduplication syndromes and on uncertain variants, as well 
as  pre- and post- test counselling approach models for prenatal CMA. 
 
Dr S. Birep Aygun presented a current overview of the state-of-the-art in non-
invasive prenatal diagnosis, and a case study on non-invasive foetal Y chromosome 
detection from maternal plasma via RT-PCR. Non-invasive molecular techniques 
include genetic analysis on foetal cells or on free foetal DNA or RNA isolated from 
maternal blood. Non-invasive genetic testing for Anti-D and foetal gender when 
mother’s genetic status is indicative is already common practice in some EU 
countries e.g. UK, the Netherlands. Non-invasive genetic tests for common 
aneuploidies like Down syndrome, Trisomy 18, and Trisomy 13 foetal DNA present 
in maternal blood are already in the market and simultaneously under 
development. If an elevated risk of chromosomal or genetic abnormality is indicated 
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by a non-invasive screening test, a more invasive technique may be employed to 
gather additional information. The case study presented demonstrates the 
feasibility and reproducibility of a biomarker system for non- invasive Y 
chromosome determination via real time PCR with 100% specificity. 
 
Dr Uysal-Onganer from the Department of Surgery & Cancer, Faculty of Medicine, 
Imperial College, London, discussed what has been done till now in UK in "Applied 
Genomics in Cancer". She underlined the fact that CMA and NGS studies have led to 
significant advances in our understanding of the cancer genome of several tumour 
types. Furthermore, current efforts are aimed at bringing sequencing discoveries 
into the clinic in the form of biomarkers (diagnostic, prognostic, and predictive) and 
biomarker-designed clinical trials. However, the new discipline of public health 
genomics, which seeks to evaluate the use of emerging genomics information 
effectively and responsibly to improve the health of individuals and populations, is 
essential. New diagnostic and predictive markers are still needed; pros and cons are 
still an issue, however a lot has been achieved considering drug response and 
tumour recurrence in certain cancer types. The stratified medicine programme by 
Cancer Research UK (CRUK) was highly praised. 
 
At the end of the second day a complete session was dedicated to Bioinformatics: 
Dr S. İşeri from Istanbul University, Dr M. Fabbri from IHCP and Mr. Ilker Karacan 
from DONE Genetics, a local genomics and bioinformatics company, presented 
various case studies that served as examples of data analysis and result 
interpretation in the field of gene expression analysis, karyotyping, linkage and Copy 
Number Variation (CNV) analysis.  
 
On the last day of the workshop a whole session was devoted to Strengths, 
Weaknesses, Opportunities, and Threats (SWOT) analysis on penetration of 
Genomic Technologies into the Clinical Services. Contributions of all participants 
were noted and results were deduced in the afternoon by Dr. Gribaldo and Dr. 
Aygun to be disseminated to the participants for review, further contribution and 
discussion. The results of the SWOT analysis serve as the basis for the 
recommendations presented in this report. 
 
 
 
4. General Conclusions 
 
 There is a clear divide between the genomic services offered in a country 
and the awareness among research scientists of the available genomic 
applications and the future impact of genomic technologies on health 
services and clinical approaches. 
 
 Medical specialists of no / minor genetic / genomic background may 
generally overlook available technologies and influence local decision 
makers in certain ways that leads to a lag in adoption of genomic tools. 
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 Establishment of the necessary infrastructure for generation, storage, 
transfer and interpretation of genomic data may be a heavy cost burden for 
target countries. 
 
 In all countries there are a number of common obstacles that delay 
penetration of genomic technologies in clinical applications: lack of 
recognised experts, lack of a regulatory framework that involves political 
determination of decision-makers, lack of common databases on methods 
and experts, lack of on-going education for physicians and most importantly 
reimbursement of testing, lag of local health impact / health technology 
assessors behind technological advancements in the field. 
 
 There is a unanimous opinion that public health in the near future is going to 
be shaped by data generated via genomic technologies. A general agreed 
upon universal definition for clinical utility and its demonstration will 
facilitate this process. 
 
 The two and a half days agenda was in general considered sufficient and 
satisfying as seen in the post event evaluation forms. There was a 
unanimous request for a next workshop. 
 
 
5. SURVEY RESULTS  
Prior to the workshop all participants had received a copy of the country expert 
survey and where kindly asked to present relevant data. The survey results are 
summarised in the Table 1 of the Annex I.  
The roundtable discussion following country presentations and presentations of 
invited speakers yielded the two technologies expected to penetrate into clinical 
services the fastest were agreed upon to be Chromosomal Microarrays and Next 
Generation Sequencing. The two areas where genomic applications are estimated 
to enter fastest into clinical services came out to be prenatal diagnosis and cancer 
genotyping/treatment. 
 
Penetration of Genomic Technologies into the Clinical Services- HOW? 
 
At the end of the workshop a whole session was dedicated to an open SWOT 
analysis on penetration of Genomic Technologies into the Clinical Services with 
contributions from all participants. 
 
SWOT Outcome  
 
Participants agreed that genomic medicine may not be cost-effective today but said 
that it may become cost-effective soon as costs go down and efficacy goes up. 
Furthermore, when people (be it a physician, patient, citizen or family member of a 
patient) are well informed on the availability of such approaches, they are usually 
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interested in the technology. Probably the correct best approach for scientists and 
clinicians would be to work closely and define the mode(s) of utilising the 
technology in such ways that are relevant, significantly contributing to the health of 
the patient and involve minimum risk or harm. 
 
Strengths: existing research environment, international collaborations, awareness 
of researchers, already trained academic personnel 
Weaknesses : lack of regulation, existing regulation stopping or lagging new 
advancements, lack of political will, lack of trained physicians, lack of hardware 
software infrastructure to maintain data, lack of trained bioinformaticians to 
analyse generated data, interpretation of results. 
Opportunities: awareness in the society (patient demand), existing bilateral, pan 
European and international networks for data and experience sharing, technology 
becoming more readily available. 
Threats: Technology platforms still too expensive, testing usually reimbursed on 
basis of price may lead to outsourcing to biotechnology company run laboratories, 
resistance of old school physicians, inability to generate reference open access 
databases. 
 
Factors most effective:  
 
 Genomic Medicine/ Personalized Medicine not always the same thing 
 Data interpretation 
 Data storage 
 Clinical implication of data 
 Education of physicians 
 Availability of open access/ public databases 
 Drug/therapy design ( individual response?) one size does not fit all 
 Who pays for the test? 
 Technology advancing rapidly 
 Research 
 Legal/ Ethical Issues 
 Clinical Implementation 
 The Industry 
 Research Funding 
 Political will/ regulation/ reimbursement 
 A number of studies already underscore the rapidly shifting landscape for 
genomic tools in the diagnostic setting. The results could influence decision 
makers to revisit guidelines concerning [prenatal] genetic testing. 
Chromosomal microarrays can provide additional clinically relevant 
information to traditional karyotyping, and will probably become a standard 
approach in prenatal diagnostics going forward. 
 Research which employs whole-genome sequencing for the clinical diagnosis 
of prenatal samples highlights how sequencing is being used increasingly for 
prenatal testing. A number of biotechnology firms, such as Sequenom, 
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Ariosa, LifeCodexx have already launched commercial tests that use 
sequencing to noninvasively detect aneuploidies in prenatal samples. 
Research results demonstrate the possibility of mapping foetal balanced 
chromosomal translocations via next generation sequencing. 
 Chromosomal microarrays will most probably be applied also in the area of 
cancer genomics, mainly covering the issue of patient dependent drug 
response and development of cancer type specific expression panels. Such 
disease specific panels are more affordable and comparatively quick yielding 
when there are no means of NGS. 
 Next generation sequencing will also play a major role in the field of cancer 
research and diagnosis, by most probably allowing cheaper and faster 
profiling.  
 Stronger connections and collaborations with the EU for research and 
technology transfer could function as leverage for these countries in 
adopting genomic tools and harmonising the quality of healthcare services 
they offer. 
 Regulations to control cross-border movement of samples should take into 
account that the patient himself is also the sample and can move freely , any 
regulation should allow if not promote ease for finding an expert centre for 
a given condition/ disease. 
 The study of rare diseases offers a way of implementing the tools and 
procedures that will later be used in more widespread applications of 
genomic medicine. 
 
Analytical validity and clinical utility 
 Increasing the sensitivity of sequencing. 
 
 There needs to be agreement upon standards for both analytical and clinical 
validation. 
 
 Clinical actions need to be determined through collaborative efforts 
involving physicians, patients, their families, and laboratories. 
 
 For genomic testing to be accepted, it should have not only analytical 
validity but also clinical and social utility. 
 
 Genomic testing should be used as a tool that is integrated with traditional 
tests for making a disease diagnosis and guiding therapy. 
 
Human genetic diversity and genetic differences between maternally and 
paternally derived chromosomes need to be considered when interpreting 
genomic data. 
 
 Pharmacogenetics results can be important for patient care, but data need 
to be carefully integrated into patient records and care processes. 
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 Sequencing devices, interpretation software packages, and testing 
laboratories will all need to meet stricter proficiency standards as genomic 
medicine progresses. 
 
Ethical issues 
 
 Patients’ genomic information should always be obtained within the 
confines of a doctor–patient relationship. 
 
 If patients are empowered to make their privacy preferences available to 
caregivers and researchers, the delivery of care and the use of patient data 
for research could both be enhanced. 
 
 Health care providers have a responsibility to provide patients with clinically 
significant genomic information but not necessarily other less clearly 
actionable information. 
 
 Patients’ concerns about confidentiality cannot be completely resolved with 
technological approaches. 
 
 Assuring patient privacy. 
 
Education and training 
 
 Education and training should focus on competencies. For a non-specialist 
health care provider, these competencies may include recognizing when a 
genomic diagnostic test is needed or how pharmacogenomics testing can 
guide decisions about therapy. 
 
 Genetics and genomics should be integrated into health professional 
education from undergraduate study through to maintenance of 
certification. 
 
 Collaborative efforts among health professionals will be essential in 
implementing genomic medicine.  
 
 
Databases and repositories 
 
 Genomic data should be put into meaningful formats in order to be most 
useful to health care providers. 
 
 Clinical data will need to be linked to genomic databases in order to further 
understanding of the phenotypic effects of genetic variants. 
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 Many laboratories do not have the resources to place their data in the public 
domain. Grant support may be necessary to move data into the public 
domain so that experts can be engaged to curate it. 
 
 Establishing a curated genomic-variant database:  who is going to curate it 
and whether the database is clinically validated. 
 
 A clinical-grade genome sequence and phenotype repository is needed first, 
and the curating at that point will revolve around collecting the proper 
information about the data being deposited. A clinical variant database can 
then be derived from those data by grading and assessing the sets of 
sequence and phenotype information in order to build decision-support 
tools. 
 
 Databases for genetic variants involved in cancer may be quicker to achieve, 
considering the more wide spread efforts for cancer inventories and 
registries. However cancer variants raise somewhat different issues than 
maintaining databases for germ line variants. Sequencing cancer genomes 
also uncovers germ line sequence information, but in sequencing cancer 
genomes there tends to be a much more direct link between acquired 
mutations and the disease. These might be interrogated specifically for 
interactions with drugs, the ability to treat, or even to prevent the 
development of tumours.  
 
 Including cancer genomes in a master database could be problematic unless 
is possible to create very definitive (CANCER) subsets among general data. 
Data should be clearly annotated to specify whether a variant has somatic 
effects, germ line effects, or both. 
 
6. ORGANISER IMPRESSIONS 
 
 The most difficult part in organising this workshop was to spot, find and 
contact experts from the target countries. Tools for professional networking 
which, allow direct access to the expert need to be devised and promoted. 
 A SWOT analysis being held during the workshop, together with the survey 
results presented by the country experts served as seed for this report 
intended to serve as a recommendation for target countries. 
 A social media connection has been formed for maintaining and continuing 
contact among all participants which, is also open for new members to join 
in order to establish a networked community.  
 Regional and International cooperation should be further enhanced, and  
guided , if possible by the EU, since this allows stronger acceptance by the 
local authorities/ decision makers in implementing new policies regarding 
public health. 
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7. RECOMMENDATIONS 
 
 It is very important to establish recognized objective state-of-the- art 
guidelines for application of genomic technologies in clinical practice. Such 
guidelines adopted by countries will form the basis of reimbursement 
policies at national and cross border levels. 
 It is very important to establish reliable, not for profit, open access 
databases for building reference datasets for correct and efficient 
interpretation of complex data generated by advanced genomic 
technologies. 
 Medical genetics has to be recognised as a medical specialty both at clinic 
and laboratory levels. 
 
 The genomics field should take a systems approach* especially to whole-
genome sequencing, which will require important changes by government, 
healthcare providers, and patients.  
 
 There should be more collaboration between clinical entities and 
laboratories, a greater emphasis on the fact that some parts of the genome 
will remain refractory to analysis, and public to laboratories to establish 
databases that can be used to refine and deliver genomic medicine.  
 
  Informatics capabilities should be leveraged to create clinical genotype–
phenotype databases, education should be improved, and reimbursement 
should be set at levels that make it possible for the healthcare system to do 
analytical thinking about how best to serve patients.  
 
 There should be greater interoperability of medical records systems 
(Electronic Health Records, EHR) so that information relevant to health care 
follows people throughout life and that genomic information is always 
accessible for further innovation.  
 
  A universal healthcare information technology system should be established 
that includes both genetic and clinical information, and barriers to data 
sharing should be reduced. 
 
 There should be funding for education, novel research to explore gene–
phenotype relationships, and improved sequencing technologies.  
 
 More emphasis should be placed on genetics and genomics in medical 
schools.  
 
 
 
* Systems approach is defined as an interdisciplinary method of study that involves 
consideration of all the components involved in a process and their interactions with each other. 
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8. ANNEX 1 
Table 1 Results of the survey  
 
1. Which of the following new/emerging 
technology platforms do you employ in 
your laboratory? 
 
a. Microarrays for expression 
profiling  mRNA/miRNA 
b. Next Generation Sequencing 
c. Real-Time PCR 
d. Array CGH 
e. More than one of these 
f. None of these 
 
a- BUL, POL, UK 
b- BUL 
c- TR, BH, CRO, POL, UK 
d- BUL, POL 
e- BUL 
f- RO 
 
 
2. Which of the following new/emerging 
technology platforms are employed 
regularly in the clinical context in your 
country ? 
 
a. Microarrays for expression 
profiling  mRNA/miRNA 
b. Next Generation Sequencing 
c. Real-Time PCR 
d. Array CGH 
e. Chromosomal microarrays 
f. None of these 
 
a- POL, UK 
b- TR, RO, UK 
c- POL, CRO, TR, RO, BUL, UK 
d- POL, TR, RO, BUL, UK 
e- UK 
f-  
3. In your opinion which technology 
platform will penetrate fastest in to 
clinical applications? Please justify very 
briefly 
 
a. Microarrays for expression 
profiling  mRNA/miRNA 
b. Next Generation Sequencing 
c. Real-Time PCR 
d. Array CGH 
e. Chromosomal Microarrays 
f. None of these 
 
a- NONE 
b- TR, RO, BUL, UK 
c- POL, BOS, RO, UK 
d- CRO, BOS, RO 
e- TUR, BUL, RO 
 
 
 
4. In your opinion which application area 
of genomic technologies will the clinic 
benefit from the earliest? Please justify 
very briefly 
 
a. Cancer genotyping 
b. Prenatal testing  
c. Preimplantation genetic diagnosis 
d. Rare diseases 
e. Personalised medicine 
f. Some other area ( please specify) 
 
a- CRO, POL, BOS, RO, BUL, UK 
b- CRO, BOS, RO, BUL, UK, TR 
c- POL, BUL, UK, TR 
d- POL, RO, UK 
e- TR, BUL 
f-  
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5. What is the scope of health/social 
security/ insurance system coverage in 
your country for : 
 
a. Prenatal testing employing 
conventional karyotyping 
b. Prenatal testing employing molecular 
karyotyping ( microarrays) 
c. Sequencing for disease diagnosis ( 
common/rare) 
d. Next generation sequencing for 
disease diagnosis (common/rare) 
e. Pharmacogenomic testing for drug 
responsiveness 
f. Preimplantation genetic diagnosis 
 
 
a- CRO, POL, BOS, TR, RO, BUL, UK 
b- POL BY SPECIAL PROGRAMMES, RO, 
UK 
c- POL AS SUPPLEMENTARY 
DIAGNOSTICS, TR, BUL, UK 
d- UK 
e- CRO, POL COVERED AS PART OF 
CANCER GENOTYPING 
f- TR FOR DISORDERS WHICH CAN BE 
TREATED BY STEM CEL 
TRANPLANTATION, UK 
 
6. Which type of testing is offered as a 
regular service by a state / private 
laboratory in your country, please 
indicate as SL or PL 
 
 
a. Prenatal testing employing 
conventional karyotyping 
b. Prenatal testing employing molecular 
karyotyping (microarrays) 
c. Sequencing for disease diagnosis 
(common/rare) 
d. Next generation sequencing for 
disease diagnosis (common/rare) 
e. Pharmacogenomic testing for drug 
responsiveness 
f. Preimplantation genetic diagnosis 
 
 
a- CRO SL/PL , POL SL/PL, BOS SL, TR 
SL/PL, RO SL/PL, BUL SL/PL, UK SL/PL 
b- POL SL/PL, TR PL, RO SL/PL, BUL PL, 
UK SL/PL 
c- POL SL/PL, BOS SL, TR SL/PL, BUL 
SL/PL, UK SL 
d- TR PL, BUL PL, UK SL 
e- CRO PL, POL SL/PL, TR PL, BUL PL 
f- POL PL, TR PL, BUL PL, UK PL 
 
 
7. How often do you collaborate with a 
laboratory outside your own country for 
research / for diagnostic purposes? 
Please state scope ( e.g. rare disease 
diagnosis, populations study, etc.)  
 
CRO : RDD ONCE EVERY THREE TO SIX 
MONTHS 
POL: RDD / RESEARCH ONCE OR TWICE A 
YEAR 
BOS : RDD UPTO 10-15 TIMES A YEAR 
TUR : RDD FEW TIMES A MONTH, RESEARCH 
ONCE A FEW YEARS 
RO: NO REPLY 
BUL: RDD ONCE A MONTH, RESEARCH ONCE 
EVERY 3 MONTHS 
8. In your opinion what is the biggest 
obstacle in your country in particular for 
penetration of genomic applications in 
clinical services ? 
 
 
CRO: ORGANISATION AND FINANCES 
POL: DISPERTION OF PROCEDURES OVER THE 
LIST OF GUARANTEED SERVICES (so called 
basket),   LACK OF COMPREHENSIVE  
FINANCIAL /EDUCATIONAL PROGRAMS 
SUPPORTING RESEARCH IN CLINICAL 
GENETICS 
BOS: LACK OF POLICIES REGULATING GENETIC 
TESTING SERVICES IN FRAME OF MEDICAL 
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DIAGNOSIS/ HEALTHCARE, LACK OF 
INVESTMENT IN THE FIELD BY PUBLIC HEALTH 
AUTHORITIES 
TUR : REIMBURSEMENT PROBLEM, 
RECOGNITION OF SERVICES BY THE SOCIAL 
SECURITY SYSTEM 
RO: POLITICAL WILL, ORGANISATION, 
EDUCATION 
BUL : SOCIAL SECURITY COVERAGE 
UK: FINANCES AND POLICIES 
 
9. Is medical genetics recognised as a 
"medical specialty branch" in your 
country's education system? 
 
CRO: ONLY FOR MEDICAL DOCTORS AS A 
CLINICAL SPECIALTY ( NO LABORATORY 
SPECIALTY, NOT OFFERED TO NON MEDICINE 
ORIGIN STUDENTS) 
POL: YES, NOT AS A LABORATORY SPECIALTY 
BOS: NO 
TUR: YES, NOT AS A LABORATORY SPECIALTY 
RO: YES  
BUL : YES 
UK: YES 
 
10. Name three measures at local 
authorities' level that will benefit 
incorporation of  genomic applications 
in healthcare services offered in your 
country 
 
CRO: 1. PRIORATISATION FOR INCLUSION 
BACKED UP BY MAPPING OF COMPETENCES, 
METHODS AND SOURCES 
2. STANDARDISATION AND HARMONISATION 
OF SERVICES ( QUALITY ASSURANCE) 
3. EDUCATION AND DISSEMINATION OF 
KNOWLEDGE 
 
POL: 1. INTRODUCTION OF A REGULATED AND 
HARMONISED QUALITY CONTROL SYSTEM 
2. LEGAL REGULATIONS THAT ALLOW MORE 
COMMON USE OF PRENATAL AND 
PREIMPLANTATION DIAGNOSTICS AND STATE 
COVERAGE 
3. MESURES TO IMPROVE COMMUNICATION 
BETWEEN THE CLINIC AND RESEARCH 
LABORATORIES 
 
BOS: 1. DEVELOPMENT OF A LIST OF MORST 
FREQUENTLY REQUIRED TYPES OF GENETIC 
TESTING AND RECOGNITION FOR PUBLIC 
HEALTH COVERAGE 
2. DEVELOPMENT OF EXPERT PANEL(S) FOR 
GENETIC COUNSELING SERVICES 
3. POLICY REGULATING QUALITY AND 
HARMONISATION OF GENETIC TESTING 
SERVICES FOR ALL LOCAL AND 
INTERNATIONALLY FUNCTIONING 
LABORATORIES 
 
TUR: 1. STANDARDISATION AND 
HARMONISATION OF QUALITY OF SERVICES 
VIA A REGISTRY 
2. RECOGNITION OF AVAILABLE TESTING AND 
PUBLIC HEALTH COVERAGE,  UPTODATE 
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HEALTH IMPACT AND TECHNOLOGY 
ASSESMENT BY INDEPENDENT EXPERT PANELS 
3. AWARENESS RAISING AMONG PHISIANS 
AND PATIENTS ( CREATE PUBLIC DEMAND 
 
RO: 1. COMPLETION AND IMPLENEMATION 
OF THE NATIONAL PLAN FOR RARE DISEAES 
2. DEFINITION AND INVENTORY FOR CENTERS 
OF EXPERTISE 
3. HARMONISED QUALITY ASSURANCE 
 
BUL: NO REPLY 
 
UK: STANDARDISATION, PUBLIC HEALTH, 
BETTER BUDGETTING (CUSTOMISED CANCER 
DRUGS) 
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Abstract 
Within the context of JRC Enlargement and Integration Activities (E&IA), the workshop "Applied genomics in the Clinic" was 
organised in Istanbul on 17-19 October 2012. The main aim of the workshop was to get an overview of the state of the art of 
applied genomics in the clinical context in accession and candidate countries, as well as new members, to share best practices in 
EU and to evaluate these in the light of a public health perspective. There is a clear divide behind the genomic services offered in 
a country and the awareness among research scientists of the available genomic applications and the future impact of genomic 
technologies on health services and clinical approaches. In all countries there are a number of common obstacles that delay 
penetration of genomic technologies in clinical applications : lack of  recognised experts ( medical genetics HAS  to be recognised 
as a medical specialty) lack of a regulatory framework that involves political determination of decision makers, lack of common 
databases on methods and experts, lack of ongoing education for physicians and most importantly reimbursement of testing. 
Stronger connections and collaborations with the EU for research and technology transfer will function as a leverage for these 
countries in adopting genomic tools and harmonising the quality of healthcare services they offer. It is very important to 
establish recognized objective state of the art guidelines for application of genomic technologies in clinical practice. Such 
guidelines adopted by countries will form the basis of reimbursement policies at national and cross border levels. In addition 
establishing reliable, not for profit, open access databases for building reference datasets for correct and efficient interpretation 
of complex data generated by advanced genomic technologies will speed up adoption of the technology in the clinic. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As the Commission’s in-house science service, the Joint Research Centre’s mission is to 
provide EU policies with independent, evidence-based scientific and technical support 
throughout the whole policy cycle. 
 
Working in close cooperation with policy Directorates-General, the JRC addresses key 
societal challenges while stimulating innovation through developing new standards, 
methods and tools, and sharing and transferring its know-how to the Member States 
and international community. 
 
Key policy areas include: environment and climate change; energy and transport; 
agriculture and food security; health and consumer protection; information society and 
digital agenda; safety and security including nuclear; all supported through a cross-
cutting and multi-disciplinary approach. 
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